Healthcare Watch List: Oncothyreon (NASDAQ:ONTY), Corcept Therapeutics Incorporated (NASDAQ:CORT), Aastrom Biosciences (NASDAQ:ASTM), Durata Therapeutics (NASDAQ:DRTX)

Corcept Therapeutics (NASDAQ:CORT) Director Longitude Venture Partners L.P sold 250,000 shares of the company’s stock on the open market in a transaction dated Friday, May 2nd. The stock was sold at an average price of $4.11, for a total value of $1,027,500.00. Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 5.06% percent to $ 4.15 yesterday on volume of 319,314 shares. The intra-day range of the stock was $ 3.80 – 4.15. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $ 417.40 million.

Aastrom Biosciences Inc (NASDAQ:ASTM) entered into a definitive agreement to acquire Sanofi’s (NYSE:SNY) Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million, with $4 million payable in cash at closing and $2.5 million payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks. Aastrom Biosciences Inc (NASDAQ:ASTM)’s stock on May 5, 2014 reported an increase of 7.38% to the closing price of $ 4.51. Its fifty two weeks range is $ 3.14 – 86.00. The total market capitalization recorded $ 27.77 million. The overall volume in the last trading session was 531,982 shares. In its share capital, Aastrom Biosciences Inc (NASDAQ:ASTM) has 6.19 million outstanding shares.

Durata Therapeutics (NASDAQ:DRTX) has been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the company, American Banking & Market News reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. On Friday, shares of Durata Therapeutics Inc (NASDAQ:DRTX) advanced 5.78% to close the day at $ 14.27. Company monthly performance is recorded as 4.08%. Durata Therapeutics Inc (NASDAQ:DRTX)quarterly revenue growth is 38.68%.

Oncothyreon (NASDAQ:ONTY)’s share price fell 7.8% during mid-day trading on Friday following a weaker than expected earnings announcement, AnalystRatings Network reports. Oncothyreon Inc (USA) (NASDAQ:ONTY) stock performance was 6.34% in last session and finished the day at $ 2.85. Traded volume was 301,661 shares in the last session and the average volume of the stock remained 852,469 shares. The beta of the stock remained 1.07. Oncothyreon Inc (USA) (NASDAQ:ONTY) insider ownership is 0.40%.